In elderly subjects at high CV risk without established CV disease statins substantially reduce the incidence CV morbidities, but do not significantly prolong survival.
Intensive Lipid-Lowering Therapy (I-LLT) is recommended in patients admitted for Acute Coronary Syndromes (ACS). However, available studies suggest that most ACS patients do not receive such treatment, while limited information is currently available as to the prescription of I-LLT in Europe. The objective of our study was to assess the use of I-LLT in patients admitted for ACS along with the persistence of such treatment 90 days after discharge. According to previous studies, I-LLT was defined as statin or combination therapy likely to produce >50% reductions in low-density lipoprotein cholesterol and included atorvastation 40 or 80 mg, rosuvastatin 20 or 40 mg, simvastatin 80 mg, or any statin of any dose used in combination with ezetimibe. This study analyzed data the NET-SCA Registry.This Registry has been designed to document the clinical epidemiology, current management and outcome of ACS in the Lazio Region of Italy (ClinicalTrials.gov Identifier: NCT01216462). Lazio is a region of central Italy with a resident population of 5,600,000. The NET-SCA registry is an initiative of the Regional Section of the Italian Association of Hospital Cardiologists (ANMCO) and is currently collecting data about consecutive admissions for ACS in 12 hospitals. The study population included 3056 consecutive ACS patients (mean age 68±13 years, 30.8% women) with complete 90-day follow-up data. I-LLT was initiated during admission in 2068 patients (67.6%); atorvastatin 40-80 mg in 1524 (73.7%), rosuvastatin 20-40 mg in 511 (24.7%) and simvastatin 80 or combination of simvastatin and ezetimibe in the remaining 33 cases (1.6%). Independent predictors of I-LLT included statin therapy before admission, history of hyperlipidemia or prior ACS, and in-hospital percutaneous coronary intervention. Overall persistence of I-LLT 90 days after discharge was 76.1%, with 493 patients completely discontinuing such treatment or switching to lower non-intensive statin doses. Moreover, the 90-day persistence was significantly lower for atorvastatin 40-80 mg (73.6%), than for rosuvastatin 20-40 mg (82.2% -relative risk reduction of 0.32; 95% confidence interval 0.17-0.45, p<0.001). In this contemporary prospective registry more than two thirds of eligible ACS patients were on I-LLT during hospitalization. Besides, more than 75% of all ACS patients receiving I-LLT during admission were still on such treatment 90 days after discharge. Finally, I-LLT with rosuvastatin 20-40 mg was associated with a higher likelihood of persistence 90 days after discharge.
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Management of lipids and blood pressure for primary prevention of cardiovascular disease in the UK: results from the EURIKA study Purpose: To evaluate the management of dyslipidaemia and hypertension in primary care in relation to current guidelines in the UK. Methods: This is a sub-analysis of UK patient data from a European cross sectional study. 69 randomly selected General Practitioners participated: 46% of them worked in an urban, 28% in a suburban and 26% in a rural primary care environment. The sub-study included 673 participants aged ≥50 years without cardiovascular disease (CVD), with at least one major cardiovascular risk factor: dyslipidaemia, hypertension, smoking, diabetes mellitus and obesity. 51% were males. Blood pressure, the use of antihypertensive and lipid lowering agents and a fasting full lipid profile were recorded. The 10-year JBS CVD risk was calculated and treatment goals evaluated according to current official guidelines for the UK. Results: Of those at high CVD risk, 41% (139 of 337) were not receiving a statin. Of the 336 individuals receiving lipid lowering therapy (LLT), Total Cholesterol (TC) was ≥ 5 mmol/L for 25%, 4-5 mmol/L for 42% and < 4 mmol/L for 33% of participants. 25% had Total Cholesterol (TC) ≥ 5 mmol/L, 42% between 4-5 mmol/L and 33% TC < 4 mmol/L; 15%, 49% and 35% had LDL-C ≥ 3 mmol/L, 2 to < 3 mmol/L and < 2mmol/L respectively. Only 6 participants (7%) of the 88 treated patients with TC ≥ 5 mmol/L and/or LDL-C ≥ 3 mmol/L and only 15 (6%) of the 244 treated participants with TC ≥ 4mmol/L and/or LDL-C ≥ 2 mmol/L were receiving high intensity statin (HIS). 459 of the 481 participants with a diagnosis of hypertension were receiving antihypertensive medication. Of the 319 without diabetes mellitus or chronic kidney disease 53% had BP ≥ 140/90mmHg, 34% (109 of 319) > 150/90mmHg, of whom two thirds were on 2 or fewer agents. Over 70% of hypertensive patients with DM and/or CKD who were receiving anti-hypertensive medication had BP higher than the more intensive target of 130/80mmHg. Conclusions: A considerable number of participants at high CVD risk are not treated with a statin despite an indication. A sizeable proportion of those receiving LLT or antihypertensive medication are not achieving targets according to current UK guidance. There is considerable potential to improve outcomes by initiating statin therapy in untreated high-risk patients and intensifying statin dose and/or adding antihypertensive agents in those with uncontrolled lipids and BP. Purpose: The extent and complexity of residual coronary stenosis has shown in previous studies to have an impact on the prognosis of patients (pts) undergoing angioplasty (PCI). The aim of this study was to quantify the extent of residual disease after coronary PCI in octogenarians with multivessel disease and to assess its impact on 1-year outcomes. Methods: We evaluated 230 pts with ≥ 80 years of age (median age 83, IQ 81-85), 60% male, 27% diabetics) and multivessel coronary disease or common trunk native undergoing PCI between January 2005 and December 2010, included in a multicentric registry. We excluded patients undergoing primary angioplasty. To establish the extent and complexity of coronary lesion, we calculated the Synergy between PCI with taxus and cardiac surgery (SYNTAX) score at baseline (bSS), the residual SYNTAX score after PCI (rSS). Patients with incomplete revascularization (rSS> 0) were stratified by tertiles. We used Kaplan Meier curves to compare the overall survival free of death and major cardiovascular events (MACE: death, MI, stroke, and revascularization) at one year follow-up. Results: From a population of 230 pts, we identified 46 (20%) with complete revascularization (CR) and 183 (80%) with incomplete revascularization (IR). Overall, the median bSS was 17 (IQR 11-23) and rSS 7 (IQR 2-13). Stratifying by tertiles the 183 pts with IR: 35 pts (19%) had SSr ≤6, 76 pts (42%) SSr 6-12 and 72 (39%) with SSr >12. With a complete follow-up in 97% of pts to one year, there were 61 patients (27%) with MACE: 10% deaths, MI, 5%, 2% and 14% stroke revascularization. There were no differences in the incidence of MACE between CR and IR groups (24% vs 27%, p=0.69). In the group IR there were no differences in the incidence of MACE over the rSS tertiles (22.6%, 27.9% and 30.6% p=0.63). Conclusions: Incomplete percutaneous coronary revascularization does not seem to have an adverse impact on 1-year ischemic events in octogenarians patients. Though, the number and complexity of residual lesions, measured by residual SYNTAX score, it is not a good predictor of prognosis in this subpopulation.
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Quantification and prognosis of incomplete coronary revascularization after percutaneous coronary intervention in octogenarians
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First-generation vs. second-generation drug-eluting stent to coronary intervention in hemodialysis patients 
